Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.55 |
| ▸ | USP30 | Q70CQ3 | 8/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23387204 | 0.93 | ALDH1A1 (0.68) | NPC1ALDH1A1MAPTMAPK1HTT | |
| SCHEMBL21624912 | 0.91 | NPC1 (0.55) | NPC1ALDH1A1MAPTMAPK1HTT | |
| SCHEMBL31439476 | 0.89 | LMNA (0.54) | NPC1ALDH1A1MAPTMAPK1HTT | |
| SCHEMBL27370167 | 0.86 | GPR119 (0.65) | GPR119USP30MEN1KMT2A | |
| SCHEMBL30718465 | 0.86 | GPR119 (0.65) | GPR119USP30MEN1KMT2A | |
| SCHEMBL29689554 | 0.86 | GPR119 (0.51) | ALDH1A1GPR119USP30MEN1KMT2A | |
| SCHEMBL29689444 | 0.85 | SIGMAR1 (0.54) | MAPTGPR119USP30MEN1KMT2A | |
| SCHEMBL21423992 | 0.85 | NPC1 (0.54) | NPC1ALDH1A1MAPTMAPK1HTT | |
| SCHEMBL13883781 | 0.84 | NPC1 (0.65) | NPC1ALDH1A1MAPTMAPK1HTT | |
| SCHEMBL21624753 | 0.84 | MEN1 (0.50) | L3MBTL1USP30MEN1KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-11-17 | — | — | US | disclosed |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1I, CACNA1G, CACNA1H | NPC1 2445/4885ALDH1A1 3434/4885MAPT 304/4885 |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | TRPV3, CACNA1G, TRPV2 | NPC1 840/4885ALDH1A1 3671/4885MAPT 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.